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Abstract
Objective: To determine the prevalence of depressive and anxiety 
symptoms in patients with rheumatoid arthritis (a chronic inflammatory 
disease) in comparison to a control group with osteoarthritis (a 
chronic non-inflammatory degenerative disease) and to identify the 
sociodemographic and clinical variables associated with depressive 
symptoms in these patients. Method: Sixty-two rheumatoid arthritis 
patients and 60 osteoarthritis patients participated in the study. 
Sociodemographic and clinical data were collected and the Hospital 
Anxiety and Depression Scale and the Disability Index of the Health 
Assessment Questionnaire were applied. Results: The prevalence of 
depressive symptoms was of 53.2% in rheumatoid arthritis and 28.3% 
in osteoarthritis (p = 0.005). The prevalence of anxiety symptoms was of 
48.4% in rheumatoid arthritis and 50.0% in osteoarthritis (p = 0.859). 
The mean (and standard deviation) scores in the Disability Index of the 
Health Assessment Questionnaire were 1.4 (0.8) in rheumatoid arthritis 
and 1.4 (0.6) in osteoarthritis (p = 0.864). Rheumatoid arthritis patients 
with depressive symptoms had lower education and higher disease activity 
and functional disability. Conclusion: Although these two rheumatic 
diseases are similar in terms of the pain and functional disability that they 
cause, a significantly higher prevalence of depressive symptoms was found 
in rheumatoid arthritis patients. This difference might be explained by the 
hypothesis of a neuroimmunobiological mechanism related to cytokines 
in inflammatory diseases, which has been considered as a candidate to 
the development of depressive symptoms. 
Descriptors: Depression; Arthritis, rheumatoid; Psychoneuroimmunology; 
Anxiety; Osteoarthritis
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Resumo
Objetivo: Determinar a prevalência de sintomas depressivos e ansiosos 
na artrite reumatoide (doença inflamatória crônica) em comparação com 
um grupo controle com osteoartrite (doença crônico-degenerativa não 
inflamatória). Identificar variáveis sociodemográficas e clínicas associadas 
a sintomas depressivos nesses pacientes. Método: Participaram do estudo 
62 pacientes com artrite reumatoide e 60 pacientes com osteoartrite. Foram 
coletados dados sociodemográficos e clínicos e foram aplicadas as escalas 
Hospital Anxiety and Depression Scale e Disability Index of the Health 
Assessment Questionnaire. Resultados: A prevalência dos sintomas 
depressivos foi 53,2% na artrite reumatoide e 28,3% na osteoartrite 
(p = 0,005). A prevalência dos sintomas ansiosos foi 48,4% na artrite 
reumatoide e 50,0% na osteoartrite (p = 0,859). Os valores médios (desvio 
padrão) de Disability Index of the Health Assessment Questionnaire foram 
1,4 (0,8) na artrite reumatoide e 1,4 (0,6) na osteoartrite (p = 0,864). 
Pacientes com artrite reumatoide e sintomas depressivos apresentaram menor 
nível educacional e maiores níveis de atividade da doença e incapacidade 
funcional. Conclusão: Embora ambas as doenças reumatológicas sejam 
similares em termos de dor e incapacidade funcional, uma prevalência 
significativamente maior de sintomas depressivos na artrite reumatoide 
foi encontrada. Essa diferença poderia ser explicada por meio da hipótese 
de um mecanismo neuroimunobiológico relacionado às citocinas nas 
doenças inflamatórias, o qual vem sendo considerado candidato para o 
desenvolvimento de sintomas depressivos.
Descritores: Depressão; Artrite reumatoide; Psiconeuroimunologia; 
Ansiedade; Osteoartrite 
Introduction
Rheumatoid arthritis (RA) is a systemic, chronic, and 
inflammatory disease with probable autoimmune etiology and 
predominant involvement of joints, characterized by symmetrical 
peripheral polyarthritis, resulting in joint deformity.1 In addition 
to producing a chronic inflammatory state, the disease generally 
causes many harmful psychosocial consequences for patients. 
Continuous pain, functional disability, tiredness, incapacity to 
work, economic limitations, and side effects of therapeutic drugs, 
which RA may bring about, can end up reducing these patients’ 
quality of life.2,3 Commonly associated with these biopsychosocial 
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problems, psychiatric symptoms -  especially depressive and anxiety 
ones - are relatively frequent in RA patients.
Several studies have identified depressive symptoms as an 
important aspect in RA. The prevalence of depressive symptoms 
in RA has been reported to vary between 6% and 65%, according 
to the screening methods used and to the samples studied.4-9 A 
recent review described a mean prevalence of 19% of depression 
among RA patients.3 Anxiety symptoms and disorders have been 
less studied separately, because they are a very frequent dimension 
of depression, making it difficult to separate anxiety symptoms 
from depressive ones.10 Some studies have found a prevalence of 
almost 40% of anxiety symptoms in RA.11
Two main hypotheses have been proposed to explain the 
association between RA and depressive manifestations: 1) the 
functional disability and poor quality of life could provoke 
the emergence of depressive symptoms or 2) a common 
neuroimmunobiological mechanism could underlie the 
development of RA and depression. This last hypothesis has been 
supported by a model according to which depressive symptoms 
and major depression are related to psychoneuroimmunological 
disturbances. The immune system activation and the resulting 
proinflammatory cytokine release have been associated with 
neurochemical, neuroendocrine, and behavioral abnormalities 
related to depressive disorders. Cytokines are causally related to 
the activation of the enzyme indoleamine-2,3-dioxygenase (IDO), 
with the consequent reduction of tryptophan (serotonin precursor) 
levels and serotonin synthesis, which is a neurochemical process 
reported to be implied in major depression. Cytokine release 
has also been linked to hypothalamic-pituitary-adrenal (HPA) 
axis hyperactivity, a neuroendocrine abnormality associated with 
depression. Finally, cytokine serum levels seem to be positively 
correlated with symptoms such as appetite loss, anorexia, weight 
loss, fatigue, sleep disturbances, motor retardation, reduced libido, 
cognitive impairment, anhedonia, and depressed mood, which 
are frequent in depressive disorders.12 Therefore, according to 
this model, the presence of depressive symptoms in RA may be 
more than a psychological reaction to the pain and functional 
disability related to the disease and may represent a dimension 
of the chronic inflammation status of RA; in this case, depressive 
symptoms would be in fact related to cytokine release itself.12-16
In order to epidemiologically survey these hypotheses, Abdel-
Nasser et al. and Bagnato et al. compared the prevalence of depressive 
symptoms in RA and osteoarthritis (OA), another chronic rheumatic 
disease that causes pain and functional disability.7,11 Differently from 
RA, OA is essentially degenerative and non-inflammatory. Both 
studies reported higher levels of depressive and anxiety symptoms 
among RA patients compared to OA ones. 
Other investigations have addressed the sociodemographic 
and clinical characteristics of RA in relation to the presence of 
depressive symptoms. These symptoms have been commonly 
associated with low levels of physical activity, low education and 
income, unemployment, functional disability, morning stiffness, 
joint pain, fatigue, duration of illness, permanent joint deformities, 
active inflammation, and high dependence on health services.5,17-19 
However, most studies have not been conclusive in regard to the 
profile of patients with RA and depressive symptoms7,8 due to 
differences in the studied samples and the heterogeneous criteria 
used to define and screen for depressive manifestations.9
The objectives of the present study were 1) to establish the 
prevalence of depressive and anxiety symptoms in RA patients 
treated at an outpatient rheumatology service in an university 
hospital; 2) to compare the prevalence of depressive and anxiety 
symptoms in RA and in a control group with OA; and 3) to 
compare two subgroups of RA patients – with and without 
depressive symptoms – concerning sociodemographic and clinical 
variables.
Method
This study comprised 122 patients from the rheumatoid arthritis 
out-patient service and the degenerative diseases outpatient 
service of the hospital of the Universidade Estadual de Campinas 
(UNICAMP). Sixty-two patients were diagnosed with RA, 
according to the American College of Rheumatology (ACR) 
criteria,20 and 60 were diagnosed with osteoarthritis (OA), based 
on clinical and radiological criteria.21 The exclusion criteria were: 
undefined RA or OA diagnosis, presence of a concomitant disease 
that can be responsible for clinical and laboratorial manifestations 
similar to those of RA or OA or likely to induce depressive and 
anxiety symptoms (cancer, use of medicines, infections, other 
immunological and rheumatologic diseases, psychiatric disorders).
The data were collected after medical appointments. When 
the inclusion and exclusion criteria were fulfilled, patients were 
invited to voluntarily participate in the study and to read and 
sign an informed consent statement. The data were collected by 
interview, questionnaire, joint exam, and copy of laboratory results 
from medical files. The selection of patients was consecutive and 
the evaluator was not blinded in regard to the rheumatologic 
diagnosis, because the patients in each group were recruited from 
different outpatient services of the same hospital. 
The sociodemographic variables assessed were gender, age, 
marital status, education, occupation, residence, religion, religious 
practice, and religiosity (faith).
Depression and anxiety symptoms were evaluated using the 
Hospital Anxiety and Depression (HAD) scale. It contains seven 
items screening for anxiety and seven for depression, rated from 
zero to three. Scores over seven in each subscale are suggestive 
of anxiety or depressive disorders.22 This scale was especially 
developed in order to avoid an overestimation of affective 
symptoms, which are frequent in physically ill patients. The 
HAD scale has been translated into Portuguese and validated for 
Brazilian samples.23,24
RA and OA patients were also assessed in regard to functional 
disability using the Disability Index of the Stanford Health 
Assessment Questionnaire (HAQ-DI), translated and validated 
for Brazilian samples.25 This scale consists of 20 questions related 
to the level of difficulty to perform daily activities, considering 
pain and joint limitations. The questions are divided into eight 
areas of daily activities and the final score is defined by adding up 
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the higher scores in each area and dividing the result by eight, so 
that the final index varies from zero to three.26 
Clinical variables from RA patients included age at onset, 
duration of illness, extra-joint manifestation, morning stiffness, 
rheumatoid factor (RF), and disease activity. The “Disease Activity 
Score” for 28 joints (DAS 28) was used to evaluate RA activity 
and to classify it as low (score < 3.2), moderate (scores between 
3.2 and 5.1) or high (score > 5.1). This score was calculated after 
four variables: number of painful joints, number of swollen joints, 
erythrocyte sedimentation rate (ESR), and visual analogue scale 
(VAS - values between 0 and 100), aiming to evaluate patients in 
a global way.27 The treatment for RA was checked in relation to 
disease-modifying anti-rheumatic drugs (DMARD) (sulfasalazine, 
methotrexate, leflunomide), glucocorticoids and/or anti-tumor 
necrosis factor (TNF)-alpha biological agents (etanercept, 
infliximab, adalimumab).28
Ethical considerations
The study was approved by the Faculdade de Ciências Médicas 
(FCM) Research Ethics Committee of the Universidade Estadual 
de Campinas (UNICAMP), under the number 165/2006.
Statistical analysis
This was an observational and cross-sectional study to 
investigate associations and compare proportions. The Chi-Square 
and Fisher’s exact test were used as necessary, and the multiple 
logistic regression analysis was adjusted according to age. The 
Shapiro-Wilk pocedure was used to test the null hypothesis that 
samples represented a normally distributed population. In order 
to compare continuous and ordinal measures between the two 
groups, the Mann-Whitney and Analysis of Variance methods 
were used for age adjustment. The level of significance was set 
at p < 0.05.
Results
Table 1 shows the sociodemographic profiles of the RA and 
OA groups. When the groups were compared, no statistically 
significant differences were found with regard to gender, marital 
status, education, occupation, residence (urban or rural), religion, 
religious practice, and religiosity (faith). However, there was a 
difference in regard to the age of the patients. 
Among RA patients, 33 (53.2%) had depression symptoms 
and 30 (48.4%) had anxiety symptoms according to the HAD 
scale. Among the patients in the OA control group, 17 (28.3%) 
presented with depression and 30 (50.0%) with anxiety. When 
the two groups were compared, a statistically significant higher 
prevalence of depressive symptoms was found in RA patients, 
which did not occur concerning anxiety symptoms (Figure 1). The 
comparison of the prevalence of depressive and anxiety symptoms 










= -0.015 for anxiety symptoms). Additionally, 40 to 60 year-
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job, and permanent job (p = 0.818)], and religiosity/faith [less, 
moderate, and much (p = 0.167)]. Concerning the treatment for 
RA, DMARD, glucocorticoids, and biological agents were checked 
as non-mutually excluding variables and there was no difference 
between groups with and without depressive symptoms related to 
drugs for RA (p = 1, 0.819 and 0.878, respectively).
Discussion
The present study indicated a high prevalence of depressive 
symptoms in RA, consonant with previous investigations.4-9 The 
prevalence of anxiety symptoms found in RA was higher than 
that expected in relation to previous evidence.11 Nevertheless, the 
present data may be overestimating the frequency of depressive 
and anxiety symptoms in RA by considering community samples. 
It should be kept in mind that the samples here investigated come 
from a university hospital, which tends to care for the most severe 
cases. On the other hand, such bias may not be relevant when the 
two conditions (RA and OA) are compared, due to the fact that 
patients came from the same care center and the two diseases have 
similar clinical severity.
In addition, it is possible that the method for measuring 
depressive and anxiety symptoms used in many studies4-9,11 might 
be accountable for the high prevalence of these features commonly 
found in RA. However, in the present study we tried to control for 
this methodological effect. Differently from other investigations, 
the depression and anxiety questionnaire used here (HAD) was 
specifically designed to screen for psychiatric symptoms in patients 
with physical diseases. Therefore, it eliminates false-positive 
responses related to somatic symptoms. Thus, the HAD seems 
to prevent the overestimation of depression and anxiety levels 
old patients were selected to homogenize the samples. As a result, 
the analysis indicated a rate of 53.3% of anxiety symptoms in 
RA versus 52.2% in OA (p = 0.933), and of 56.7% of depressive 
symptoms in RA versus 30.4% in OA patients (p = 0.057). In these 
new analyses, despite the reduction in the statistical significance, a 
tendency for higher depression scores in RA than in OA continued 
to be observed.
There was no statistically significant difference between groups 
in relation to the level of functional disability. RA patients 
presented a mean (and standard deviation) HAQ-DI score of 1.4 
(0.8) - median of 1.4, maximum equal to 3.0 and minimum 0 - 
and OA patients presented a mean score of 1.4 (0.6) - median of 
1.4, maximum equal to 2.9 and minimum 0 (Figure 2).
In the next phase, RA patients were divided into two groups 
– with and without depression – according to the scores in the 
HAD scale, and compared in terms of sociodemographic, clinical, 
functional disability, and treatment variables. The overall clinical 
profile of RA patients consisted of a mean (SD) age at onset of 
35.5 (13.9) years, mean duration of illness of 15.6 (13.0) years, 
extra-joint manifestation of 29.0%, morning stiffness of 85.5%, 
positive rheumatoid factor of 69.4%, DAS 28 of 4.8 (1.7), and 
HAQ-DI of 1.37 (0.83).
There were no statistical differences between the groups 
with and without depressive symptoms concerning gender, 
age, residence (urban or rural), religion, religious practice, 
and clinical variables. However, RA patients with depressive 
symptoms presented a lower educational level, a higher disease 
activity rate (taking into account not only the prevalence of high 
disease activity, but also DAS 28 scores), and a higher functional 
disability index than patients without depressive symptoms (Table 
2). Furthermore, the groups were not different in relation to marital 
status (p = 0.891), occupation [unemployed, housewife, temporary 
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in patients with organic conditions and comorbid anxiety and 
depressive symptoms, such as RA and OA patients.
Comparing the RA and OA groups, the prevalence of depressive 
symptoms in the former was higher than in the latter (p = 0.005). 
This did not occur in relation to anxiety symptoms, which were 
similar in both groups. There were no differences concerning most 
of the sociodemographic characteristics that could influence the 
prevalence of depressive and anxiety symptoms, except the mean age. 
There was a reduction in the significance of the higher 
prevalence of depression in RA versus OA after the adjustment for 
age. However, in all the analyses conducted, depressive symptoms 
were more prevalent in RA than in OA, and this difference had 
either statistical significance or tendency. It is probable that a 
type II error has occurred here, i.e. the number of patients in the 
groups selected was not sufficient to detect a statistically significant 
difference, although it might exist29 as suggested by the comparison 
without adjustment for age.
Another purpose of this study was to analyze which variables 
were related to depressive symptoms in RA patients. The results 
revealed that depressive symptoms are associated with low 
educational level, high disease activity, and high functional 
disability. Low educational levels are commonly associated with 
lower professional expectations, purchasing power, access to 
leisure, and understanding about one’s own disease (RA) – facts 
that may explain the higher rates of depressive complaints in 
some individuals. Moreover, higher HAQ-DI scores in patients 
with depressive symptoms may suggest that RA-related functional 
disability is also responsible for the high frequency of depressive 
manifestations in this disease. 
High functional disability levels resultant from RA and/or a 
possible neuroimmunobiological mechanism could explain the 
high frequency of depressive symptoms found in RA. In order to 
investigate the hypothesis that considers depression as secondary 
to the physiopathology of RA, the prevalence of depressive 
symptoms in RA was compared with the prevalence of depressive 
symptoms in a disease with a similar impact, but presenting a 
different physiopathology from RA. OA also causes pain and joint 
deformities in patients; however, it is predominantly chronic-
degenerative and not inflammatory like RA. In this comparison, 
both patient groups presented the same levels of impairment and 
suffering, that is, similar levels of functional disability stemming 
from pain and joint deformities, demonstrated by similar average 
HAQ-DI scores in the OA and RA groups. On the other hand, 
the prevalence of depressive symptoms was higher in RA than in 
OA. Therefore, this difference could be due to the inflammatory 
nature of RA, characterized by increased proinflammatory cytokine 
release, which would cause neurochemical, neuroendocrine, and 
behavioral changes associated with depression.12
It was already expected that depressive symptoms in RA would 
be related to high disease activity, measured with the DAS 28. 
The more active RA is, the greater the inflammation, cytokine 
release, and functional disability associated with it, a cluster of 
biological phenomena that may be one of the most relevant aspects 
of depression in RA. 
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This study has some methodological limitations which must 
be considered in the analysis of the results. There are some 
variables that were not evaluated here and that could influence 
the comparison of the prevalence of depressive symptoms in RA 
versus OA, such as age at onset and duration of illness. Moreover, 
the use of some drugs can induce depressive and anxiety symptoms 
(e.g. corticosteroids and immunosuppressants). The HAD scale 
identifies only current depressive and anxiety symptoms, and 
although it can suggest a diagnosis of depressive or anxiety 
disorders, it is unable to establish such a diagnosis. The absence 
of confirmed diagnoses and the lack of data about age at onset 
of major depression, which could be compared with age at onset 
of RA, are factors that limit a possible cause-effect analysis. 
Furthermore, it was not the scope of this study to confirm or to 
refute the hypothesis that depressive symptoms are secondary 
to a neuroimmunobiological mechanism. Similarly, it was not 
methodologically possible to suggest any direct relationship 
between these results and a neuroimmunobiological theory 
associating RA and depressive symptoms.
The present findings suggest that the emergence of depressive 
symptoms in RA patients is not only related to subjective suffering 
and physical limitations caused by the disease. In this context, it is 
plausible that a neuroimmunobiological mechanism, among other 
possible factors, could be associated with the development of depressive 
symptoms. This study may, therefore, contribute to an integrated and 
psychosomatic view for the comprehension of RA, taking into account 
the high frequency of depressive symptoms present in this condition.
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